ReviewProbiotics and antimicrobial proteins2026
Postbiotics: Modulation of the Gut Microbiota and Potential for Association with Nanotechnology.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shaping the Future of Microbial Therapies Through Intelligent Probiotic and Postbiotic Delivery.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postbiotics are preparations containing inanimate microorganisms or their components that have a direct or indirect beneficial effect on the host and can include many different components, such as short-chain fatty acids, bacterial lysates, cell-free culture supernatants, cell wall fragments, enzymes, and exopolysaccharides. Despite the numerous advantages of postbiotics for the body, their use is limited due to unfavorable pharmacokinetics, low bioavailability, non-selective pharmacological action, poor palatability, and unpleasant odor. The development of nanotechnology-based delivery systems could be an important industrial tool to enhance the selective action of these agents and improve their therapeutic efficacy, particularly in the pharmaceutical and food sectors. In the pharmaceutical industry, several nanotechnology-based delivery systems have already been approved by the FDA and successfully marketed, demonstrating their clinical and industrial viability, such as Abraxane®, Doxil® (or Caelyx®), Onivyde®, Marqibo®, and Vyxeos®. In the food industry, products such as Driphorm® (nanostructured lipid emulsion for the efficient delivery of vitamin D in food) illustrate how nanotechnology has been applied in concrete ways to the development of functional foods and nutraceuticals, contributing to technological innovation, added value, and advances in health promotion. However, although nanotechnology in the delivery of postbiotics is an emerging and innovative field with promising preclinical studies, the lack of consolidated clinical or commercial data means that this topic needs to be expanded in order to achieve standardization and clinical validation. This review aims to highlight the importance of postbiotics in the modulation of gut microbiota and in the prevention/treatment of disease, as well as the potential of using nanotechnology to facilitate the targeting of these compounds and the limitations of using these systems for such applications.
Indexed as
Identifiers
40679568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.